[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100593609":3},{"organization":4,"armGroups":7,"interventions":30,"overallOfficials":10,"centralContacts":35,"locations":45,"responsibleParty":72,"collaborators":75,"id":79,"slug":80,"hasResults":81,"nctId":82,"briefTitle":83,"officialTitle":83,"acronym":10,"eligibilityCriteria":84,"healthyVolunteers":85,"sex":86,"minAge":87,"maxAge":10,"enrollmentInfo":88,"targetDuration":10,"studyType":91,"phases":10,"briefSummary":92,"conditions":93,"keywords":98,"overallStatus":48,"whyStopped":10,"lastUpdateSubmitDate":100,"lastUpdatePostDateStruct":101,"startDateStruct":104,"completionDateStruct":106,"leadSponsor":108,"locationsCount":109},{"fullName":5,"class":6},"University of Maryland, Baltimore","OTHER",[8,14,18,22,26],{"label":9,"type":10,"description":11,"interventionNames":12},"Study Population 1",null,"This study population will consist of individuals who have a new diagnosis of lung cancer and have not received chemotherapy treatment for their lung cancer. Individuals who have received surgical resection or stereotactic body radiation therapy (SBRT) for their lung cancer will be included.",[13],"Other: Epigenetic Signature Assay",{"label":15,"type":10,"description":16,"interventionNames":17},"Study Population 2","This study population will consist of individuals who have a diagnosis of lung cancer and have received chemotherapy treatment for their lung cancer. All stages of lung cancer will be included including individuals in remission.",[13],{"label":19,"type":10,"description":20,"interventionNames":21},"Study Population 3","This study population will consist of individuals who are at high risk of developing lung cancer, such as people with a long smoking history, and are receiving yearly lung screening scans.",[13],{"label":23,"type":10,"description":24,"interventionNames":25},"Study Population 4","This study population will consist of individuals who may be hospitalized for another condition such as pneumonia or heart failure at time of enrollment into the study. Individuals who have a greater than 10 pack year history of smoking will not be included in this population.",[13],{"label":27,"type":10,"description":28,"interventionNames":29},"Study Population 5","This study population will consist of individuals who have no other significant medical problems.",[13],[31],{"type":6,"name":32,"description":33,"armGroupLabels":34,"otherNames":10},"Epigenetic Signature Assay","Up to 15 ml of blood will be collected from each patient at various time points throughout their 5 years of participation. DNA extraction, bisulfite conversion and analysis of epigenetic markers through PCR or next-generation sequencing will be performed. An epigenetic signature assay will then be identified.",[9,15,19,23,27],[36,41],{"name":37,"role":38,"phone":39,"phoneExt":10,"email":40},"McKenzie Bedra, MPH","CONTACT","410-553-8184","McKenzie.Bedra@umm.edu",{"name":42,"role":38,"phone":43,"phoneExt":10,"email":44},"Jennifer Emel, MA","410-553-8048","Jennifer.Emel@umm.edu",[46],{"facility":47,"status":48,"city":49,"state":50,"zip":51,"country":52,"countryCode":53,"cosmosGeoPoint":54,"geoPoint":59,"contacts":60},"University of Maryland Baltimore Washington Medical Center","RECRUITING","Glen Burnie","Maryland","21061","United States","US",{"type":55,"coordinates":56},"Point",[57,58],-76.62469,39.16261,{"lat":58,"lon":57},[61,65,67,70],{"name":62,"role":38,"phone":63,"phoneExt":10,"email":64},"Jeffrey Marshall, MD","410-787-4000","Jeffrey.Marshall@umm.edu",{"name":62,"role":66,"phone":10,"phoneExt":10,"email":10},"PRINCIPAL_INVESTIGATOR",{"name":68,"role":69,"phone":10,"phoneExt":10,"email":10},"Peter Olivieri, MD","SUB_INVESTIGATOR",{"name":71,"role":69,"phone":10,"phoneExt":10,"email":10},"Darwin Ashbaker, MD",{"type":66,"investigatorFullName":73,"investigatorTitle":74,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Jeffrey Marshall","Chair, Division of Pulmonary and Critical Care Medicine; Associate Chair, Department of Medicine",[76],{"name":77,"class":78},"EPOCH Epigenetics, Inc","UNKNOWN","100593609","signature-development-and-validation-protocol-for-an-epigenetic-assay-in-diagnosing-lung-cancer-100593609",false,"NCT07008664","Signature Development and Validation Protocol for an Epigenetic Assay in Diagnosing Lung Cancer","Inclusion Criteria:\n\n* 18 years old or older\n* Patient at University of Maryland Baltimore Washington Medical Center\n* Willing and able to consent to study procedures listed in the protocol\n* Ability to speak and understand English\n\nExclusion Criteria:\n\n* Younger than 18 years old\n* Patient not cared for at University of Maryland Baltimore Washington Medical Center\n* Unable to consent to study procedures listed in the protocol\n* Unable to speak or understand English",true,"ALL","18 Years",{"count":89,"type":90},750,"ESTIMATED","OBSERVATIONAL","The purpose of this research study is to test a new process for diagnosing lung cancer by examining changes to your DNA that can be detected from a blood test. The information we learn by doing this study could potentially help people in the future.\n\nParticipants in this study will have blood samples collected, have their medical records reviewed by study personnel and fill out questionnaires at different time points during the study. Blood sample collection will occur during normal routine clinic visits. Participation in this study will last approximately 5 years.",[94,95,96,97],"Lung Cancer","Lung Cancer Screening","Healthy Volunteers (HV)","Unhealthy Volunteers",[94,95,99,97],"Healthy Volunteers","2025-06-05",{"date":102,"type":103},"2025-06-11","ACTUAL",{"date":105,"type":103},"2025-03-31",{"date":107,"type":90},"2032-04",{"name":5,"class":6},1]